BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia

British Journal of Haematology

Volumn 149, Issue 3, 2010, Pages 458-460

  Lucas, Claire M ^a   Harris, Robert J ^a   Giannoudis, Athina ^a   Knight, Katy ^a   Watmough, Sarah J ^a   Clark, Richard E ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Biomarker; CML; Imatinib; PCrkL; PCrkL CrKL ratio

Indexed keywords

BCR ABL PROTEIN; CRK LIKE PROTEIN; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE;

CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOGENETICS; ENZYME ACTIVITY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LETTER; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PIPERAZINES; PROGNOSIS; PROSPECTIVE STUDIES; PYRIMIDINES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77950802395     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.08066.x     Document Type: Letter

References (9)

1. Davies, A., Jordanides, N.E., Giannoudis, A., Lucas, C.M., Hatziieremia, S., Harris, R.J., Jørgensen, H.G., Holyoake, T.L., Pirmohamed, M., Clark, R.E. C., M.J. (2009) Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia, 23, 1999 2006.
2. Kantarjian, H.M., Giles, F., Gattermann, N., Bhalla, K., Alimena, G., Palandri, F., Ossenkoppele, G.J., Nicolini, F.-E., O'Brien, S.G., Litzow, M., Bhatia, R., Cervantes, F., Haque, A., Shou, Y., Resta, D.J., Weitzman, A., Hochhaus, A. le Coutre, P. (2007) Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood, 110, 3540 3546.
3. de Lavallade, H., Apperley, J.F., Khorashad, J.S., Milojkovic, D., Reid, A.G., Bua, M., Szydlo, R., Olavarria, E., Kaeda, J., Goldman, J.M. Marin, D. (2008) Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. Journal of Clinical Oncology, 26, 3358 3363.
4. Lucas, C.M., Wang, L., Austin, G.M., Knight, K., Watmough, S.J., Shwe, K.H., Dasgupta, R., Butt, N.M., Galvani, D., Hoyle, C.F., Seale, J.R.C. Clark, R.E. (2008) A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia, 22, 1963 1966.
5. Lucas, C.M., Harris, R.J., Giannoudis, A., Davies, A., Knight, K., Watmough, S.J., Wang., L. Clark, R.E. (2009) Chronic myeloid leukaemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib than e14a2 patients. Haematologica, 94, 1362 1367.
6. O'Hare, T., Walters, D.K., Stoffregen, E.P., Jia, T., Manley, P.W., Mestan, J., Cowan-Jacob, S.W., Lee, F.Y., Heinrich, M.C., Deininger, M.W.N. Druker, B.J. (2005) In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants. Cancer Research, 65, 4500 4505.
7. Patel, H., Marley, S.B. Gordon, M.Y. (2007) Conventional Western blotting techniques will not reliably quantify p210BCR-ABL1 levels in CML mononuclear cells. Blood, 109, 1335.
8. Wang, L., Giannoudis, A., Lane, S., Williamson, P., Pirmohamed, M. Clark, R.E. (2008) Expression of the Uptake Drug Transporter hOCT1 is an Important Clinical Determinant of the Response to Imatinib in Chronic Myeloid Leukemia. Clinical Pharmacology and Therapeutics, 83, 258 264.
9. White, D., Saunders, V., Lyons, A.B., Branford, S., Grigg, A., To, L.B. Hughes, T. (2005) In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood, 106, 2520 2526.